Eli Lilly | LLY - Operating Profit


Eli Lilly reported $9.78B in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Abbott USD 1.85B 399M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Baxter International USD 66M 280.2M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Medtronic USD 2.09B 354M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sanofi EUR 1.5B 2.29B Dec/2025
United Therapeutics USD 325.8M 340.4M Mar/2026
Zoetis USD 865M 30M Mar/2026